Literature DB >> 14630792

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Jan Cools1, Hilmar Quentmeier, Brian J P Huntly, Peter Marynen, James D Griffin, Hans G Drexler, D Gary Gilliland.   

Abstract

We recently identified the chimeric kinase FIP1L1-platelet-derived growth factor receptor alpha (PDGFRalpha) as a cause of the hypereosinophilic syndrome and of chronic eosinophilic leukemia. To investigate the role of FIP1L1-PDGFRA in the pathogenesis of acute leukemia, we screened 87 leukemia cell lines for the presence of FIP1L1-PDGFRA. One cell line, EOL-1, expressed the FIP1L1-PDGFRA fusion. Three structurally divergent kinase inhibitors--imatinib (STI-571), PKC412, and SU5614--inhibited the growth of EOL-1 cells. These results indicate that the fusion of FIP1L1 to PDGFRA occurs rarely in leukemia cell lines, but they identify EOL-1 as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and for the analysis of small molecule inhibitors of FIP1L1-PDGFRalpha.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14630792     DOI： 10.1182/blood-2003-07-2479

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  26 in total

Review 1.  FIP1L1/PDGFR alpha-associated systemic mastocytosis.

Authors:  Yoshiyuki Yamada; Jose A Cancelas
Journal:  Int Arch Allergy Immunol       Date:  2010-06-04       Impact factor: 2.749

2.  ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.

Authors:  Carmen P Montano-Almendras; Ahmed Essaghir; Hélène Schoemans; Inci Varis; Laura A Noël; Amélie I Velghe; Dominique Latinne; Laurent Knoops; Jean-Baptiste Demoulin
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

3.  JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

Authors:  Thomas Mercher; Gerlinde Wernig; Sandra A Moore; Ross L Levine; Ting-Lei Gu; Stefan Fröhling; Dana Cullen; Roberto D Polakiewicz; Olivier A Bernard; Titus J Boggon; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

4.  The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.

Authors:  Yoshiyuki Yamada; Marc E Rothenberg; Andrew W Lee; Hiroko Saito Akei; Eric B Brandt; David A Williams; Jose A Cancelas
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

5.  Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.

Authors:  Joseph M Gozgit; Matthew J Wong; Scott Wardwell; Jeffrey W Tyner; Marc M Loriaux; Qurish K Mohemmad; Narayana I Narasimhan; William C Shakespeare; Frank Wang; Brian J Druker; Tim Clackson; Victor M Rivera
Journal:  Mol Cancer Ther       Date:  2011-04-11       Impact factor: 6.261

6.  Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

Authors:  Els Lierman; Cedric Folens; Elizabeth H Stover; Nicole Mentens; Helen Van Miegroet; Werner Scheers; Marc Boogaerts; Peter Vandenberghe; Peter Marynen; Jan Cools
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

7.  Leukotactin-1/CCL15 induces cell migration and differentiation of human eosinophilic leukemia EoL-1 cells through PKCdelta activation.

Authors:  Ji-Sook Lee; In Sik Kim
Journal:  Mol Biol Rep       Date:  2009-08-11       Impact factor: 2.316

8.  Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.

Authors:  Keisuke Miyazawa; Naoki Kakazu; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

9.  Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data.

Authors:  Ahmed Essaghir; Federica Toffalini; Laurent Knoops; Anders Kallin; Jacques van Helden; Jean-Baptiste Demoulin
Journal:  Nucleic Acids Res       Date:  2010-03-09       Impact factor: 16.971

10.  Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect.

Authors:  Jun Fan; Hee-Bum Kang; Changliang Shan; Shannon Elf; Ruiting Lin; Jianxin Xie; Ting-Lei Gu; Mike Aguiar; Scott Lonning; Tae-Wook Chung; Martha Arellano; Hanna J Khoury; Dong M Shin; Fadlo R Khuri; Titus J Boggon; Sumin Kang; Jing Chen
Journal:  J Biol Chem       Date:  2014-08-07       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.